ArticleCNS drugs2022

Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".

Azmi Nasser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.